https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41023 Wed 08 Nov 2023 09:37:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7349 Sat 24 Mar 2018 08:40:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20955 Sat 24 Mar 2018 08:06:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17525 Sat 24 Mar 2018 08:03:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5537 T polymorphism located within the promoter region of the ΔDNMT3B gene has recently been reported to be associated with a significant increase to the risk of early onset CRC. In this study we determined the ΔDNMT3B genotype in 404 confirmed HNPCC participants (total of 194 CRC cases) from Australia (203) and Poland (201). Front the total number of participants there were 194 diagnosed cases of CRC and 210 healthy MMR gene Mutation carriers. The study was undertaken to assess whether the reported effect observed in a previous study of 146 HNPCC patients is consistent in a larger separate and unrelated participant cohort. Through the statistical tests of Kaplan-Meier survival analysis and Cox hazard regression models we did not observe any significant association between the ΔDNMT3B C>T SNP and early onset CRC in HNPCC patients.]]> Sat 24 Mar 2018 07:46:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4736 T polymorphism in the VEGF gene and its association with sporadic breast cancer risk has been analyzed in various studies yielding conflicting results. To analyze the role of this polymorphism in modifying hereditary breast and ovarian cancer risks, we conducted a case-control study and genotyped 755 Polish BRCA1 carriers, including 319 breast cancer cases, 146 ovarian cancer cases, and 290 unaffected controls. The results revealed an association of the CT + TT genotypes with a reduced breast cancer risk (ORadj 0.63, 95% CI, 0.41-0.98; ORclustered 0.63, 95% CI, 0.48-0.83), and a potential effect on ovarian cancer risk (ORadj 0.62, 95% CI, 0.33-1.18; ORclustered 0.62, 95% CI, 0.47-0.83). Thus, the 936_C>T polymorphism appears to modify disease risks in BRCA1 carriers.]]> Sat 24 Mar 2018 07:21:09 AEDT ]]>